Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women

被引：17

作者：

Kittaneh, Muaiad ^{[1
]}

Gluck, Stefan ^{[1
]}

机构：

[1] Univ Miami, Leonard M Miller Sch Med, 1475 NW 12th Ave,Suite 3310, Miami, FL 33146 USA

来源：

BREAST CANCER-BASIC AND CLINICAL RESEARCH | 2011年 / 5卷

关键词：

aromatase inhibitor; breast cancer; exemestane; disease-free survival; tamoxifen;

D O I：

10.4137/BCBCR.S6234

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P < 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.

引用

页码：209 / 226

页数：18

共 113 条

[1]

AMIR E, 2010, 33 ANN SAN ANT BREAS

[2] Comparison of age distribution patterns for different histopathologic types of breast carcinoma [J].

Anderson, William F. ;

Pfeiffer, Ruth M. ;

Dores, Graca M. ;

Sherman, Mark E. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (10) :1899-1905

[3] Early discontinuation of tamoxifen - A lesson for oncologists [J].

Barron, Thomas I. ;

Connolly, Roisin M. ;

Bennett, Kathleen ;

Feely, John ;

Kennedy, M. John .

CANCER, 2007, 109 (05) :832-839

[4]

Bartlett JM, 2009, CANC RES S3, V69

[5]

Bartlett JMS, 2010, 33 ANN SAN ANT BREAS

[6] Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen [J].

Bertelli, G. ;

Hall, E. ;

Ireland, E. ;

Snowdon, C. F. ;

Jassem, J. ;

Drosik, K. ;

Karnicka-Mlodkowska, H. ;

Coombes, R. C. ;

Bliss, J. M. .

ANNALS OF ONCOLOGY, 2010, 21 (03) :498-505

[7] Exemestane in postmenopausal women with early or advanced breast cancer: a review [J].

Bertelli, Gianfilippo ;

Gangadhara, Sharath .

EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) :1933-1942

[8] The discovery and mechanism of action of letrozole [J].

Bhatnagar, Ajay S. .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 105 (Suppl 1) :7-17

[9] Lost opportunities: Physicians' reasons and disparities in breast cancer treatment [J].

Bickell, Nina A. ;

LePar, Felice ;

Wang, Jason J. ;

Leventhal, Howard .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2516-2521

[10] Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio [J].

Blaha, Peter ;

Exner, Ruth ;

Dal Borgo, Andrea ;

Bigenzahn, Sinda ;

Panhofer, Peter ;

Riedl, Otto ;

Schoppmann, Sebastian ;

Bachleitner-Hofmann, Thomas ;

Sporn, Emanuel ;

Pluschnig, Ursula ;

Fitzal, Florian ;

Steger, Guenther ;

Jakesz, Raimund ;

Dubsky, Peter ;

Gnant, Michael .

BREAST CARE, 2009, 4 (03) :155-161

← 1 2 3 4 5 6 7 8 9 10 →